Company Reports / Eli Lilly and Company LTD

COMPANY: Eli Lilly and Company LTD

INDEX RANK: 17th

Total Impact Score: 8,863.27

Eli Lilly and Company LTD is ranked 17th place in our index for 2015. Eli Lilly and Company LTD’s drugs have a total impact score of 8,863.27. Eli Lilly and Company treats one disease in our model - XDR-TB - with one total drug - Capreomycin (Cm). Eli Lilly and Company receives credit for one treatment against XDR-TB - Capreomycin (Cm). This one drug averted 8,863.27 of the total DALYS for XDR-TB, which is 12.50% of the worldwide DALYs that we estimate would have been lost due to XDR-TB in 2015 in the absence of effective treatment. Eli Lilly and Company’s drug portfolio placed it in a tie for 3rd in terms of total averted DALYs for XDR-TB.

Company Score Breakdown:

Key Drugs

CAPREOMYCIN (CM)

Capreomycin (Cm), a cyclic peptide antibiotic, is a second-line injectable agent recommended in the treatment of rifampicin-resistant and multidrug-resistant tuberculosis. It is proven effective against TB and has a moderate safety profile, although aminoglycosides are generally favored over capreomycin. Side effects include hearing loss and damage to the kidneys. Cm was patented by Eli Lilly & Co. in 2007.

Company Information

Colonel Eli Lilly founded Eli Lilly and Company in 1876. Lilly, a global pharmaceutical company headquartered in Indiana, focuses its efforts in the areas of oncology, immunology, diabetes care, chronic pain, Alzheimer’s disease and animal health. The company maintains the Lilly Open Innovation Drug Discovery Program, useful for scientists researching various diseases including multidrug-resistant tuberculosis. It was the first company to mass produce the Salk polio vaccine, insulin, and Prozac®, as well as the first to develop capreomycin. Lilly works to improve access to medicine by using differential pricing schemes, waving property rights in least-developed countries and through donations on products delivered via the Lilly TruAssist program and Life for a Child. Their products are currently sold in nearly 125 countries and include Trulicity®, Humalog®, and Alimta®. The company employs about 38,000 workers and in 2017, Eli Lilly reported revenue of over $19.97 billion.

Company Report PDF

CONTACT US © 2017 GLOBAL HEALTH IMPACT